BeStock  

Takeda Pharmaceutical TAK

US equityMarket cap rank #310Infectious Disease
$21.77 +$0.36 (+1.68%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $22.09 +1.47%
Open$21.82
Prev close$21.41
Day range$21.74 – $22.07
Volume3.80M
Market cap$69.76B
P/E (TTM)311.0
Dividend yield1.44%
Founded1781
CEOMs. Julie Kim
Employees47,029
HeadquartersOsaka, Japan
Websitewww.takeda.com

About

Takeda is a Japanese drugmaker with products in gastrointestinal, rare disease, neuroscience and oncology, and plasma-derived therapies.

What tends to move the stock

Patent expiry of Vyvanse and growth of newer products are the central issues.

Revenue per employee

$38.0M$58.9M$79.9M$100.9MMar '19Mar '22Mar '26

47,029 employees as of 2026/FY (-0.9% YoY). Revenue per employee is total revenue divided by headcount — a rough productivity gauge, not a per-worker pay figure.

Management team

Milano Furuta Director and Chief Financial Officer
Age 48 · Total comp. $384,000,000.00 · As of 16 Jun 2026
Background

Milano Furuta has been Takeda's Chief Financial Officer since April 2024. He was appointed as a Director in June 2024. Mr. Furuta joined Takeda in 2010 and has worked on various projects in corporate strategy, corporate development, and post-merger integration in Japan and Switzerland. He managed the Diabetes Business Unit in Mexico and served as General Manager in Sweden. He went on to serve as Corporate Strategy Officer and Chief of Staff in Japan for two years and President, Japan Pharma Business Unit for three years before his appointment to CFO. Prior to joining Takeda, Mr. Furuta worked as an equity research analyst at Taiyo Pacific Partners L.P. in the United States. He began his career in banking and private equity investment at The Industrial Bank of Japan, Limited (currently Mizuho Financial Group, Inc.) in Japan, where he was involved with several types of financial transactions, including leveraged buyouts and debt restructuring.

Masami Iijima Chairman of the Board
Age 76 · Total comp. $43,000,000.00 · As of 16 Jun 2026
Background

Masami Iijima served as External Director who is a member of the Audit and Supervisory Committee of Takeda from June 2021 to June 2022, and was appointed External Director of Takeda and Chair of the Board of Directors in June 2022. Mr. Iijima currently also serves as Executive Advisor of Mitsui & Co., Ltd., External Director of SoftBank Group Corp., Counsellor at Bank of Japan and External Director of Kajima Corporation. Mr. Iijima started his career at Mitsui & Co., Ltd. in April 1974. At Mitsui & Co., Ltd., he served in several senior leadership positions including Chairman of the Board of Directors and Representative Director, President and Chief Executive Officer.

Kimberly A. Reed Independent Director
Age 55 · Total comp. $40,000,000.00 · As of 16 Jun 2026
Background

Kimberly A. Reed was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2022. She currently also serves as Distinguished Fellow of Council on Competitiveness, External Director of Momentus, Inc. and External Director of Hannon Armstrong Sustainable Infrastructure Capital, Inc. Ms. Reed previously served as Counsel for United States House of Representatives, Senior Advisor to United States Secretaries of the Treasury, Director and Chief Executive Officer of Community Development Financial Institutions Fund, Vice President, Financial Markets Policy Relations of Lehman Brothers, President of International Food Information Council Foundation, and Chairman of the Board of Directors, President, and Chief Executive Officer of Export-Import Bank of the United States.

Miki Tsusaka Independent Director
Age 63 · Total comp. $38,000,000.00 · As of 16 Jun 2026
Background

Miki Tsusaka was appointed External Director of Takeda in June 2023. She currently also serves as President of Microsoft Japan Co., Ltd. Prior to joining Microsoft Japan, she was a Senior Partner and Managing Director at Boston Consulting Group (BCG). She established strategic consulting groups specializing in marketing, sales and pricing strategy development and led the expansion of BCG's service areas. As for BCG's operation, she was a member of the Executive Committee for two three-year terms and served as Chief Marketing Officer (CMO) as well.

Dr. Steven Gillis, PhD Independent Director
Age 73 · Total comp. $38,000,000.00 · As of 16 Jun 2026
Background

Steven Gillis has been an External Director with Takeda since January 2019. Prior to his appointment, he was an External Director of Shire plc. He also currently holds the positions of Managing Director at ARCH Venture Partners and serves as a director of private biotechnology companies, including eGenesis, Walden Biosciences, HiberCell, Lifordi Immunotherapeutics and Sonothera. Dr. Gillis previously served as External Director and Chairman at Codiak BioSciences, Inc. and VBI Vaccines, Inc. He was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporation.

Dr. John M. Maraganore,PhD Independent Director
Age 64 · Total comp. $38,000,000.00 · As of 16 Jun 2026
Background

John Maraganore was appointed External Director of Takeda in June 2022. He is the Principal and CEO of JMM Innovations, LLC., and the Co-CEO of privately held Corsera Health, Inc. He currently also holds External Directorships at Beam Therapeutics, Inc., and Kymera Therapeutics, Inc. and Rapport Therapeutics, Inc. He previously served as Director and CEO of Alnylam Pharmaceuticals, Inc., Senior Vice President and Strategic Product Development at Millennium Pharmaceuticals, Inc., External Director at ProKidney Corporation and Chairperson of Biotechnology Innovation Organization.

Dr. Andrew S. Plump, M.D.,PhD Director and President, Research and Development
Age 61 · Total comp. $12,000,000.00 · As of 16 Jun 2026
Background

Andrew S. Plump, M.D., Ph.D., is the President of Research and Development at Takeda. Dr. Plump joined Takeda as Chief Medical and Scientific Officer (CMSO) in 2015. In his position, he leads our global research and development organization, where he provides strategic direction and oversight. Prior to joining Takeda, Dr. Plump served as Senior Vice President, Research and Translational Medicine, Deputy to the President of research and development at Sanofi, where he was responsible for global research and translational medicine across all therapeutic areas. Dr. Plump also spent more than 10 years at Merck in a Clinical Pharmacology group, working on programs in neurodegeneration, immunology, metabolism and infectious diseases.

Ramy Riad President, Plasma-Derived Therapies Business Unit
Age 51 · As of 16 Jun 2026
Background

Ramy Riad is President of Plasma-Derived Therapies (PDT) Business Unit of Takeda Pharmaceutical Company Limited. A global biopharmaceutical leader with more than 20 years of experience spanning strategy, finance, operations and market access, Mr. Riad brings deep expertise in the plasma industry. Most recently, Mr. Riad served as Senior Vice President and CFO of Finance, Strategy, and Operations for the PDT Business Unit, where he helped shape Takeda's end-to-end plasma value chain strategy. He also helped build an integrated operating model spanning plasma collection, manufacturing, R&D, strategy and commercial operations strengthening alignment, accountability and performance through significant industry and supply chain disruption during the COVID-19 pandemic. Earlier at Takeda, Mr. Riad led international commercial finance across eight regions, 106 countries, and 60 affiliates, driving commercial execution, market penetration, and organizational integration. Prior to joining Takeda, Mr. Riad held multiple leadership roles at Abbott, Merck, and Sanofi Aventis, working across global market access, pricing, reimbursement, and institutional strategy. Mr. Riad holds an MBA in Finance from Southern New Hampshire University and a bachelor's degree in Accounting and Business Administration from Cairo University.

Julie Kim Chief Executive Officer, President and Director
Age 56 · As of 16 Jun 2026
Background

Julie Kim is CEO-Elect and a member of Takeda Executive Team of Takeda Pharmaceutical Company Limited. Ms. Kim joined Takeda in 2019 through the acquisition of Shire and has held several diverse roles with increasing responsibility, including President of Plasma-Derived Therapies Business Unit and President of U.S. Business Unit. With three decades of experience working in health care and leadership positions at the global, regional, country and functional levels, Ms. Kim's experiences have spanned a variety of therapeutic areas, international market access, country and regional general management, marketing and emerging market development. Ms. Kim is known for a strong, collaborative and inclusive leadership style that enables Takeda to meet the needs of the people Takeda serves while driving innovations that will improve patients' lives. Her global outlook, a result of having worked in many countries in Europe, Asia and Latin America, as well as having lived in the U.K., Switzerland and the U.S., has helped her foster diverse teams to enable inclusive decision-making that keeps the patient at the center. A committed community leader, she participated in the Massachusetts Governor's Economic Development Planning Council in 2023 as the lead for the Life Sciences working group and will serve on the Governor's newly created advisory commission for the Discovery, Research, and Innovation for a Vibrant Economy (DRIVE) initiative to advise on ways to strengthen the Massachusetts research and innovation ecosystem. She was appointed by the Mayor of Boston to the Board of Trustees of the Boston Public Library, one of the most iconic and respected institutions in the city. She also serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA) and is a member of the Council of Korean Americans. Ms. Kim earned an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a bachelor's degree in economics from Dartmouth College. On January 30, 2025, our Board of Directors unanimously resolved to appoint Ms. Kim as the successor to Christophe Weber, President, Chief Executive Officer (CEO) and Representative Director, upon Mr. Weber's retirement from Takeda, expected in June 2026. Ms. Kim has been proposed as a candidate for election to our Board of Directors at the annual general meeting of shareholders to be held in June 2026.

Akiko Amakawa Chief Executive Officer Chief of Staff
Age 54 · As of 16 Jun 2026
Background

Akiko Amakawa is CEO Chief of Staff for Takeda Pharmaceutical Company Limited. Ms. Amakawa most recently served as corporate strategy officer & CEO chief of staff, overseeing Corporate Strategy, the CEO office, Board of Directors operations, and Corporate Governance. In this role, she worked closely with senior leadership and the Board to shape Takeda's enterprise strategy and strategic priorities. Since joining Takeda in 2018, Ms. Amakawa has played a key role in advancing the company's corporate development and external innovation strategy. She previously led Global Business Development across Gastrointestinal & Inflammation, Neuroscience, and Vaccines, where she was responsible for several high-impact transactions, including Takeda's acquisition of Nimbus Therapeutics' TYK2 program (TAK-279). She also helped establish strategic partnerships with Moderna and Novavax and supported the collaboration with the Government of Japan to secure COVID-19 vaccine supply during the pandemic. Ms. Amakawa brings more than 20 years of experience in corporate development, M&A, business development, and corporate strategy across the pharmaceutical, life Sciences, technology and automotive sectors in Japan, the U.S. and China. Ms. Amakawa holds an MBA from The Wharton School of the University of Pennsylvania and a bachelor's degree in economics from the University of Tokyo.

Lauren Duprey Chief Transformation Officer
Age 42 · As of 16 Jun 2026
Background

Lauren Duprey is Chief Transformation Officer of Takeda Pharmaceutical Company Limited with responsibility for connecting transformation across the Company, including AI initiatives. She previously served as Takeda's Chief Human Resources (HR) Officer and Head of HR for the U.S. Business Unit. Since joining Takeda, Ms. Duprey has implemented a transformation of HR, including a new operating model, structure, capabilities and technology. Prior to joining Takeda, Ms. Duprey served as Head of HR, U.S. Organization & Worldwide Medical at Biogen where she developed and drove the talent and organization strategy and served as a trusted advisor for key business, talent and organizational decisions. She has held various HR roles at companies such as General Electric and began her career in management consulting at Clarion Healthcare focusing on biopharma commercialization. Ms. Duprey holds a bachelor's degree in biology from Harvard University and an MBA from Massachusetts Institute of Technology (MIT) Sloan School of Management.

Gabriele Ricci Chief Data and Technology Officer
Age 48 · As of 16 Jun 2026
Background

Gabriele Ricci is Chief Data and Technology Officer of Takeda Pharmaceutical Company Limited. He was appointed to this role in February 2022 and leads the transformation of Takeda's Data, Digital and Technology division. Mr. Ricci joined Takeda in 2019 as Head of Plasma-Derived Therapies IT, during which he drove initiatives to meet the large and growing demand for plasma-derived products, with highly specialized services that require strategic capacity, innovative business models, dedicated R&D and agile supply allocation on a global scale. Prior to joining Takeda, Mr. Ricci served as Head of Digital Health and Emerging Technology at Shire, where he leveraged new and emerging technologies to optimize internal operations and deliver differentiated patient and customer experiences. Mr. Ricci has also served as Shire's Head of Technical Operations IT and held leadership positions at Novartis, Johnson & Johnson and Bristol-Myers Squibb. Mr. Ricci brings more than 20 years of information technology and engineering expertise in the life sciences industry and sits on several advisory boards for non-profit organizations focused on digital, life sciences and manufacturing. Mr. Ricci holds an MBA from the MIB Trieste School of Management and a bachelor's degree in engineering from the University of Rome Tor Vergata.

Giles Platford President, International Business Unit
Age 48 · As of 16 Jun 2026
Background

Giles Platford is President of International Business Unit of Takeda Pharmaceutical Company Limited, where he directly oversees all markets outside of the U.S., to better position the company for long-term growth and to maximize the patient impact of Takeda's current and future portfolio across diverse international markets. Mr. Platford joined Takeda in 2009 as General Manager of Brazil, and later took on the role of Area Head for the Middle East, Turkey & Africa. He then joined the Takeda Executive Team in 2014 as President of Emerging Markets. In 2017, he became President of Europe & Canada, where he also represented Takeda as a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). In 2022, he became President of the Plasma-Derived Therapies Business Unit, where he also represented the company as chair of the global executive board for the Plasma Protein Therapeutics Association. He also serves as a board member of the Healthcare Businesswomen's Association. Prior to joining Takeda, Mr. Platford spent eight years in Asia Pacific, where he held a number of roles of increasing responsibility in Business Development, Commercial and General Management. Mr. Platford holds a Bachelor of Arts degree in business and marketing management from Oxford Brookes University, UK, and is currently based in Boston, U.S.

Elaine Shannon President, Global Supply and Quality
Age 52 · As of 16 Jun 2026
Background

Elaine Shannon is President of Global Supply & Quality of Takeda Pharmaceutical Company Limited, where she leads internal and external manufacturing, supply chain and quality activities across the Company's manufacturing network to ensure uninterrupted and sustainable supply of Takeda's product portfolio. Most recently, she served as global quality officer from 2023 to 2026, where she oversaw the quality organization, embedding a consistent, enterprise quality management system as well as strengthening a culture of quality. In that role, Ms. Shannon also initiated a transformation of the global quality organization, including a new operating model and capabilities. Ms. Shannon has held roles of increasing responsibility at Takeda, where she has honed her expertise in quality, manufacturing, and oncology. Additionally, she has served as Head of Takeda's Massachusetts Biologics Operations manufacturing site, as well as Global Head of Quality Oncology & External Supply Small Molecules and Global Head of Quality Audits and Supplier Management. She joined Takeda's global quality compliance and systems group in June 2016 to develop the company's knowledge management processes. Ms. Shannon has more than 25 years of industry experience in quality, compliance, assurance and R&D, including work with Teva Pharmaceuticals and Pinewood Healthcare. Outside of Takeda, Ms. Shannon is involved in industry and community leadership through her membership in the Parenteral Drug Association (PDA) and her service on the Board of Directors of Associated Industries of Massachusetts (AIM). She holds a master's degree in pharmaceutical manufacturing technology and a bachelor's degree in Good Manufacturing Practice (GMP).

Natalie Furney Global General Counsel
Age 47 · As of 16 Jun 2026
Background

Natalie Furney is Global General Counsel and a member of Takeda Executive Team of Takeda Pharmaceutical Company Limited. Ms. Furney joined Takeda in April 2025. Before joining Takeda, she held various strategic leadership roles at Eli Lilly and Company, most recently as senior vice president and deputy general counsel, where she provided strategic legal counsel to the International Business Unit and Regulatory leadership teams. She also partnered with Ethics & Compliance, HR and Finance to enhance risk mitigation strategies and led the International Legal and Regulatory Legal teams, developing talent and driving organizational excellence. Ms. Furney's 14-year career at Lilly included transforming the Litigation, Investigations and HR Legal teams, as well as leading cross-functional issue management teams in crisis situations. Her leadership resulted in best-in-class legal strategies for the organization. Ms. Furney holds a Juris Doctor degree from Valparaiso University School of Law and a bachelor's degree in journalism and political science from Indiana University - Bloomington. She is admitted to the Indiana Bar and the United States District Court, Southern District of Indiana.

Koichiro Kimura Independent Director
Age 63 · As of 16 Jun 2026
Background

Koichiro Kimura is a candidate for an External Director who is an Audit and Supervisory Committee Member to be appointed in June 2026. He currently also serves as Representative at Koichiro Kimura Certified Public Accountant Office and External Director who is an Audit and Supervisory Committee Member at MUFG Bank, Ltd. External Audit and Supervisory Board Member of Fujitsu Limited. Mr. Kimura started his career as a Certified Public Accountant at Aoyama Audit Corporation in October 1986. He has previously served as Representative Executive Officer at PricewaterhouseCoopers Arata and has held leadership positions at PwC Japan, PwC Asia Pacific and PwC Global.

Marcello Agosti Interim Head, Strategy and Portfolio Development
Age 55 · As of 16 Jun 2026
Background

Marcello Agosti is Interim Head of Strategy and Portfolio Development for Takeda Pharmaceutical Company Limited and is responsible for Takeda's business development activities, including M&A and Corporate Development. Mr. Agosti led the Shire acquisition and several other strategic acquisitions for Takeda, including ARIAD Pharmaceuticals, and TiGenix as well as asset acquisitions such as TAK-279 from Nimbus Therapeutics and fruquintinib from HUTCHMED. He also spearheaded a number of strategic divestments of non-core assets as part of Takeda's commitment after the Shire acquisition. Mr. Agosti and his group continue to be active on inbound transactions in Takeda's core therapy areas. Prior to joining Takeda, Mr. Agosti worked in business development at Novartis in the U.K. and Switzerland. Before joining the pharmaceutical industry, he was a consultant at McKinsey & Company. He holds an MBA from the University of Oxford and a business administration degree from Bocconi University, Milan.

Jennifer Smoter Chief Communications and Governance Officer
Age 54 · As of 16 Jun 2026
Background

Jennifer Smoter is Chief Communications & Governance Officer of Takeda Pharmaceutical Company Limited, leading a centralized Global Communications & Governance organization covering internal and external communications, brand leadership, a governance center of excellence, sustainability, and CEO Chief of Staff responsibilities. Jennifer is responsible for safeguarding Takeda's brand and reputation, deepening trust with stakeholders, and helping shape the external environment in support of Takeda's strategy. She also ensures strong corporate governance, including close coordination with Takeda's Board of Directors. Ms. Smoter joined Takeda in 2026 and has brought nearly three decades of diverse experience in communications, corporate affairs, brand and community and social responsibility. Most recently, Jennifer served as chief communications officer at UnitedHealth Group, where she led a team through advancing Takeda's reputation and navigating complex challenges. Previously, she served as chief external affairs officer at Intellia Therapeutics and held numerous senior communications and brand roles at AbbVie and Abbott Laboratories. Ms. Smoter holds a bachelor's degree from Alverno College and was inducted into the PR Week Hall of Fame in 2024. She is a World 50 Communications member, an Arthur W. Page Society for Communications Professionals seminarian. Jennifer sits on the advisory board of Reversal Therapeutics.

Nicola Greenway Chief Human Resources Officer
Age 57 · As of 16 Jun 2026
Background

Nicola Greenway is Chief Human Resources (HR) Officer of Takeda Pharmaceutical Company Limited with responsibility for delivering an exceptional people experience across the globe. She joined Takeda in 2012 and has served as Head of HR for the Global Portfolio Division, Head of HR for Global Manufacturing Supply and Quality, Head of HR for the Middle East, Turkey and Africa and Global Head of Talent Development and Organizational Effectiveness. Ms. Greenway brings more than 25 years of global experience in HR spanning leadership roles at KPMG and HSBC. Originally from the Caribbean, she has lived and worked in Dubai, London and Zurich. Ms. Greenway is a passionate mentor and coach, with a deep commitment to diversity, equity and inclusion. She was an executive sponsor of Takeda's Gender Parity Network and represents Takeda on the Healthcare Businesswomen's Association Global Board of Directors, serving as chair of the Board. Ms. Greenway holds a Bachelor of Science and a Master of Science degree, a Master of Arts in business and management, a master's degree in employment law from the University of Surrey, and an executive MBA from ENPC, Paris and the University of Edinburgh.

Asuka Miyabashira President, Japan Pharma Business Unit
Age 47 · As of 16 Jun 2026
Background

Asuka Miyabashira is President of Japan Pharma Business Unit of Takeda Pharmaceutical Company Limited. Ms. Miyabashira joined Takeda in 2004 and has served in roles of increased responsibility in marketing and medical in Japan and other countries. Her experiences include leading regional sales in Japan as well as important international assignments, such as country manager at Takeda Vietnam, where she led the development of the local business strategy and transformation. Prior to this role, she served as business operation manager at Takeda Indonesia to build the foundation for Takeda Oncology's new product launch and access strategy. She served as Head of Neuroscience Business Unit within Japan Pharma Business Unit for two years before the appointment to her current role. Ms. Miyabashira holds an MSc in Agriculture from Kyushu University, Japan.

Bruce D. Broussard Independent Director
Age 64 · As of 16 Jun 2026
Background

Bruce Broussard is a candidate for an External Director who is an Audit and Supervisory Committee Member to be appointed in June 2026. He currently also serves as Interim Chief Executive Officer at HP Inc. and External Director at March & McLennan Companies, Inc. Mr. Broussard previously served as Founder and Chief Executive Officer at Harbor Dental, President of Specialty Pharmacy Division at McKesson Corporation and President and Chief Executive Officer at Humana Inc. He has also held several leadership positions at US Oncology, Inc., including Chief Financial Officer, President, Chief Executive Officer and Chairman.

Dr. Rhonda Pacheco, PhD President, U.S. Business Unit and U.S. Country Head
Age 47 · As of 16 Jun 2026
Background

Rhonda Pacheco is President of Takeda's U.S. Business Unit and U.S. Country Head, and a member of Takeda's Executive Team. She leads a portfolio spanning gastroenterology, neuroscience, plasma-derived therapies and rare diseases, driving Takeda's largest market in alignment with the company's global strategy. A Pharmaceutical Doctor and business leader with more than 20 years of experience across multiple countries and roles, Dr. Pacheco brings strategic acumen, operational excellence and people-first leadership. She joined Takeda from Eli Lilly, where she served as Group Vice President of U.S. Cardiometabolic Health. In that role, she built high-performing teams focused on improving patient outcomes, advancing health equity and expanding access to life-changing medicines. She also oversaw complex portfolios and product launches, including Lilly's GLP-1 portfolio, delivering strong commercial results. Dr. Pacheco is passionate about uniting diverse teams around a shared purpose. Her leadership aligns with Takeda's values, purpose and vision, fostering teams that deliver meaningful impact for patients, partners and communities. A Massachusetts native, Dr. Pacheco holds an MBA from Duke University's Fuqua School of Business and a Doctor of Pharmacy from the University of Rhode Island.

Teresa Marie Bitetti President, Global Oncology Business Unit
Age 64 · As of 16 Jun 2026
Background

Teresa Bitetti is President of Global Oncology Business Unit and a member of Takeda Executive Team of Takeda Pharmaceutical Company Limited, where she oversees a global portfolio of therapies targeting gastrointestinal, thoracic and hematological cancers. In this role, Ms. Bitetti leads all aspects of Takeda's multi-billion-dollar oncology business, with major markets in the US, Europe and Japan. With a proven track record in product development, launch excellence and successful commercialization, Ms. Bitetti is recognized for her ability to drive product growth in both emerging and mature markets. Her leadership has been instrumental in launching blockbuster medicines and in inspiring and mobilizing teams to deliver exceptional performance. Ms. Bitetti's commercial expertise and experience in building and accelerating pipelines has consistently delivered value for patients. Since joining Takeda, she has led the launch of a medicine for patients with previously treated metastatic colorectal cancer and secured approvals for Takeda Oncology therapies in new indications in lymphoma, leukemia and lung cancer. Her strategic vision has strengthened Takeda's oncology portfolio through the execution of impactful business development partnerships and close collaboration with R&D to translate scientific discoveries into meaningful therapies. Before joining Takeda, Ms. Bitetti was Senior Vice President and Head of Worldwide Oncology Commercialization at Bristol Myers Squibb (BMS). At BMS, she was pivotal in launching the blockbuster lung cancer treatment Opdivo, accelerating the oncology pipeline and developing the long-term strategy for the immuno-oncology portfolio. Her experience at BMS also included leadership roles in infectious diseases and neuroscience, where she successfully launched the blockbuster medicine Abilify. While at BMS, she served as Senior Vice President and Head of U.S. Oncology, President and General Manager of BMS Canada and Worldwide Head of BMS Virology. Prior to BMS, Ms. Bitetti was part of the Capital Markets Group at Mobil Oil Corporation, overseeing the investment of Mobil's worldwide pension assets. In addition to her role at Takeda, Ms. Bitetti serves on the Board of Directors for Aura Biosciences, a biotech developing precision therapies for solid tumors designed to preserve organ function. She is also on the Board of Trustees for Northwestern Mutual, a financial services company specializing in insurance and investment products. Ms. Bitetti earned her MBA from the Darden School of Business at the University of Virginia and her BA from Wellesley College.

Dr. Awny Farajallah, M.D. Chief Medical Officer
Age 58 · As of 16 Jun 2026
Background

Awny Farajallah, M.D. is Chief Medical Officer for Takeda Pharmaceutical Company Limited. Dr. Farajallah joined Takeda in July 2021 as the Head of Global Medical Affairs Oncology. He is a strategic leader with over 25 years of combined experience in both academic and industry settings related to clinical research/development and medical affairs across multiple therapeutic areas. Before joining Takeda, Dr. Farajallah worked at Ipsen, where he was Senior Vice President of Medical Affairs, North America. During his tenure, he led efforts to enhance Medical Affairs capabilities with the goal of broadening the impact on patients through medical stakeholder partnerships across Oncology, Neuroscience and Rare Disease. Prior to Ipsen, Dr. Farajallah served as Vice President and Head of U.S. Medical Affairs at Bristol Myers Squibb, where he led functions such as field medical, disease areas, medical education, biomarkers, promotional material review, portfolio strategy, as well as strategic collaborations across oncology, immunoscience, cardiovascular and neurology. He led multiple successful launches in immuno-oncology and hematology, was the clinical development lead for hematological malignancies in leukemia and multiple myeloma and led the global medical and clinical development teams for HIV. Dr. Farajallah earned his M.D. from Cairo University and completed an Internal Medicine residency and Infectious Diseases fellowship at the University of Arkansas for Medical Sciences and the New Jersey Medical School, respectively.

Dr. Paulus Stoffels, M.D. Independent Director
Age 64 · As of 16 Jun 2026
Background

Paul Stoffels is a candidate for an External Director and Substitute Audit and Supervisory Committee Member to be appointed in June 2026. He currently also serves as International Board Member at The Foundation for the National Institutes of Health, Vice Chairman of the Supervisory Board at Philips Healthcare NV and Executive Director at Stoffels IMC BV. Dr. Stoffels previously served as Chairman and Chief Executive Officer at Galapagos NV. He has also held several leadership positions at Johnson & Johnson, including Global Head of Research & Development of Pharmaceuticals, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Vice Chairman of the Executive Committee.

From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.

Sectors & themes

Discussion

No comments yet — be the first to weigh in on TAK.

Sign in to join the discussion.

Scroll to Top